Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

Abstract Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset
Alzheimer's disease (LOAD), leading to earlier age of clinical onset and exacerbating …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …

We identified a PSEN1 (presenilin 1) mutation carrier from the world's largest autosomal
dominant Alzheimer's disease kindred, who did not develop mild cognitive impairment until …

INTRODUCTION Alzheimer's disease (AD) is characterized by amyloid plaques in the brains
of patients. The primary components of amyloid plaques are β-amyloid peptides (Aβs) …

The cerebellum has long been regarded as essential only for the coordination of voluntary
motor activity and motor learning. Anatomical, clinical and neuroimaging studies have led to …

This review is concerned with the role of fibrillization of the amyloid β (Aβ)-peptide in
Alzheimer's disease (AD). The perspective is that of a physical chemist, and one aim is to …

Epigenetics is a quickly growing field encompassing mechanisms regulating gene
expression that do not involve changes in the genotype. Epigenetics is of increasing …

The dominant hypothesis of Alzheimer's disease (AD) aetiology, the neuropathological
guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both …